Four Vanderbilt technologies earned U.S. patent protection in February. They are:
8,658,650 - Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allostericpotentiators, compositions, and methods of treating neurological dysfunction, developed by P. Jeffrey Conn, Craig W. Lindsley, Corey R. Hopkins, Charles David Weaver, Colleen M. Niswender, Rocco D. Gogliotti, Darren W. Engers with the Vanderbilt Center for Neuroscience Drug Discovery.
8,655,431 – Apparatus and method for real-time imaging and monitoring of an electrosurgical procedure, developed by Karen Joos and Jin Hui Shen of the Vanderbilt Eye Institute and M. Shane Hutson and John Kozub in the Physics and Astronomy Department.
8,652,218 – Powered leg prosthesis and control methodologies for obtaining near normal gait, developed by Michael Goldfarb, Huseyin Atakan Varol, Frank Charles Sup, IV, Jason Mitchell, and Thomas J. Withrow in the Department of Mechanical Engineering.
8,647,827 – Fluorescent substrates for neurotransmitter transporters, developed by Randy D. Blakely in the Department of Pharmacology, John N. Mason, Ian D. Tomlinson and Sandra J. Rosenthal in the Department of Chemistry.